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Abstract 
 
Background 
Wide variation exists in inter-hospital survival from out-of-hospital cardiac arrest (OHCA). Regionalisation of care 
into cardiac arrest centres (CAC)may improve this. We report a pilot randomised trial of expedited transfer to a 
CAC following OHCA without ST-elevation.The objective was to assess the feasibility of performing a large-scale 
randomised controlled trial. 
 
Methods 
Adult witnessed ventricular fibrillation OHCA of presumed cardiac cause were randomised 1:1 to either: 1) 
treatment: comprising expedited transfer to a CAC for goal-directed therapy including access to immediate 
reperfusion, or 2) control: comprising current standard of care involving delivery to the geographically closest 
hospital. The feasibility of randomisation, protocol adherence and data collection of the primary (30-day all-cause 
mortality) and secondary (cerebral performance category (CPC)) and in-hospital major cardiovascular and 
cerebrovascular events (MACCE)) clinical outcome measures were assessed.  
 
Results 
Between November 2014 and April 2016, 118 cases were screened, of which 63 patients (53%) met eligibility 
criteria and 40 of the 63 patients (63%) were randomised. There were no protocol deviations in the treatment 
arm. Data collection of primary and secondary outcomes was achieved in 83%. There was no difference in 
baseline characteristicsbetween the groups: 30-day mortality (Intervention 9/18, 50% vs. Control 6/15, 40%; 
P=0.73), CPC 1/2 (Intervention 9/18, 50% vs. Control 7/14, 50%; P>0.99) or MACCE (Intervention 9/18, 50% vs. 
Control 6/15, 40%; P=0.73). 
 
Conclusions 
These findings support the feasibility and acceptability of conducting a large-scale randomised controlled trial of 
expedited transfer to CAC following OHCA to address a remaining uncertainty in post-arrest care.  
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Introduction 
Out-of-hospital cardiac arrest (OHCA) is a global public health issue. There are 60,000 OHCA per year in the 
United Kingdom and over 400,000 in the United States.1-3There is wide variation in both regional and inter-
hospital survival rates from OHCA and overall survival remains poor, with a reported average of 7%.4 The 
adoption of systematic approaches to post-resuscitation care may improve long-term survival from OHCA.5,6 
Regionalisation of care into specialist centres has played a vital role in the management of time-critical illnesses 
through concentration of services and greater provider experience.7-14 Coronary artery disease is responsible for 
>70% of OHCA, with an acute occlusion demonstrated in 50% of consecutive patients taken immediately to 
coronary angiography.15 Multi-faceted interventions including early cardiopulmonary resuscitation (CPR) and 
defibrillation, followed by timely reperfusion are associated with reducedrisk of re-arrest, reduced myocardial 
dysfunction and thus improved outcomes followingcardiac arrest from ST-elevation (STE) myocardial 
infarction.16-18The International Liaison Committee on Resuscitation (ILCOR) suggests transport of all post-arrest 
patients to a cardiac arrest centre (CAC) with 24/7 access to interventional cardiology facilitiesto manage the 
ensuing cardiovascular dysfunction and to diagnose and treat the underlying cause with a view to increasing 
survival.19-22The management of cardiac arrest survivors without STE,however, is controversial, with a less time-
sensitive approach to cardiac catheterisation. Because of the lack of randomised data, there has been variable 
uptake of such a strategy amongst the interventional cardiology community. ILCOR states that randomised trials 
are therefore essential in this population to determine if timely delivery to a CAC improves survival.23However, 
the coordination of this is complex and close interaction is necessary between centres and ambulance services 
and internally between the emergency department, cardiologists and the critical care team. We performed 
A(pilot) Randomised tRial of Expedited transfer to a cardiac arrest centre for non-ST elevation OHCA(ARREST) 
of presumed cardiac cause to assess the safety and feasibility of conducting a large-scale randomised controlled 
trial in patients without STE. 
Methods 
This was a pilot multi-centre prospective randomised controlled trial undertaken in London, United Kingdom by 
London Ambulance Service (LAS) and St Thomas Hospital (for system characteristics see online supplemental 
information). All adult witnessed out-of-hospital pulseless ventricular tachycardia (VT) or ventricular fibrillation 
(VF) cardiac arrests without obvious non-cardiac cause (trauma, drowning, suicide, poisoning) attended by the 
advanced paramedic practitioners in a pre-hospital setting were considered eligible for inclusion. Randomisation 
was performed following 3 cycles of CPR regardless of return of spontaneous circulation (ROSC). Refractory VF 
was defined as refractory to shock and drug treatment following 3 cycles of CPR. Patients were excluded from 
the trial if at the point of randomisation they had evidence of STE on the post-resuscitation ECG, the initial 
rhythm was asystole or pulseless electrical activity (PEA), a do not attempt resuscitation order was in place or 
suspected pregnancy. 
 
Before randomisation, patient management followed standard pre-hospital ALS guidelines. Eligible patients were 
randomly allocated with the use of sequentially numbered opaque, tamper-proof sealed envelopes 
(sealedenvelope.com) with pre-assigned random permuted blocks of ten, stratified according to site (advanced 
paramedic car). Randomisation was performed 1:1 to one of two parallel trial arms: intervention or control. The 
intervention arm consisted of activation of the pre-hospital triaging system (currently routinely in place for STE 
patients only) with pre-alert and delivery of the OHCA patient to the catheter laboratory at the dedicated CAC(24 
hours a day, 7 days a week). Patients were transported to hospital with or without ROSC. Patients who achieved 
ROSC received guideline-recommended post-resuscitation care including targeted temperature management 
(36°C 28 hours, followed by gradual rewarming at 0.5°C per hour)24and goal-directed therapies. These included 
evaluation and identification of the underlying cause of arrest with access to immediate reperfusion if necessary 
and maintenance ofnormocapnia and normoxiawith protective ventilation, optimisation of haemodynamics as well 
as maintenance of normoglycaemia.25 
 
The control arm comprised the current standard of pre-hospital care for patients with cardiac arrest of suspected 
cardiac aetiology as per LAS Cardiac Care Guidance Protocol (supplemental data). Patients were conveyed to 
the closest emergency department and management thereafter followed standard hospital protocol. In the 
absence of non-cardiac cause, and in the absence of futility, coronary angiography wasrecommended within 48-
72 hours in the control arm if not performed sooner (evidence of STE or high-suspicion of on-going infarction at 
the discretion of the physician).  
 
The primary objective of this pilot trial was to assess the feasibility of a randomised trial in OHCA without STE 
comparing expedited transfer to a CAC with the current standard of care to assess a difference in 30-day 
mortality. Feasibility outcome measures included recruitment rate, protocol adherence and the ability to obtain 
case-report form specific data on participants. The primary clinical endpoint was 30-day all-cause mortality. 
Secondary clinical endpoints comprised 1) good neurological function at discharge, capped at 30 days according 
to the cerebral performance category(CPC), the most commonly used post-resuscitation outcome measurement 
for this purpose.26 2) The composite of in-hospital major adverse cardiovascular events(MACE) capped at 30 
days, defined as: re-infarction27, further revascularisation and bleeding.  
 
Prior to data analysis, the following additions were made to the trial secondary outcomes to capture all adverse 
events: 1) MACE was modified to include cerebrovascular events – termed MACCE. 2) Sepsis, defined as two or 
more components of the systemic inflammatory response syndrome.28 
 
Trained research staff at St Thomas Hospital collected trial related data. The trial was managed and coordinated 
by the London School of Hygiene and Tropical Medicine Clinical Trials Unit (LSHTM CTU). The study was 
granted ethical approval by the United Kingdom National Research Ethics Committee (REC 13/LO/1508). Due to 
the specific nature of the trial and the immediacy of the intervention, the committee waived the need for prior 
informed consent.  At the earliest appropriate time, the participant or their legal surrogate were asked for delayed 
consent. The trial was prospectively registered with the International Standard Randomised Controlled Trials 
Registry (ISRCTN 96585404). 
Statistical Analysis 
Statistical analysis, based on intention to treat, was performed usingStatPlus (AnalystSoft, USA) and Prism 
version 7.0 (GraphPad Software Inc, USA). The sample size (n=40) was selected to allow an assessment of the 
feasibility of recruitment and implementation of trial processes.29The pilot study was not powered to detect 
important differences. However, categorical data were compared using Fisher’s exact test; continuous data were 
compared by 2-sample t-test. The treatment groups were compared for the primary endpoint of all-cause 
mortality 30-days after randomisation using odds ratios with 95% confidence intervals (CI). The Kaplan-Meier 
survival curves were drawn to assess differences between groups for the time to an event data examining all-
cause mortality at 30 days.All p values were 2 sided. 
 
Results 
Patient Population and Feasibility 
118 cases were screened, of which 63 patients (53%) met eligibility criteria. Forty of the 63 patients (63%) were 
randomised over two separate time periods: November 2014 to March 2015 (10 patients) and August 2015 to 
February 2016 (30 patients). Full data were available on 36 patients (90%); reasons for exclusion are detailed in 
the patient flow diagram (Figure 1), displayed according to Consolidated Standards of Reporting Trials 
(CONSORT) recommendation. The trial was stopped at 40 patients because the planned sample size to assess 
trial feasibility was reached. All randomised patients completed the trial. All patients in the Intervention arm were 
delivered direct to St Thomas Hospital cardiac catheter lab; patients in the control arm were delivered to the 
emergency department (ED) in one of 6 hospitals in London: St. Thomas Hospital, St. Mary’s Hospital, Chelsea 
and Westminster Hospital, King’s College Hospital, Royal Free Hospital, Royal London Hospital. One patient in 
the control arm did not reach hospital (online supplement). After randomisation, 4 patients (10%) were found to 
meet exclusion criteria (the presence of ST-elevation on the post-resuscitation ECG). However, for the intention 
to treat analysis, all patients were analysed in the group they were randomised to regardless of this or eventual 
crossover or other protocol deviation. Only one patient was identified as having a non-cardiac cause of arrest 
(end-stage renal failure) and did not survive to hospital. All other patients had a cardiac cause of arrest.One 
patient had aortic dissection that was managed within the specialist centre, ten patients were identified as having 
a scar-related arrhythmiaeither due to previous infarct or heart muscle disease (requiring implantable 
cardioverter defibrillator implantation on admission) and the rest were directly due to coronary artery disease.  
 
Baseline characteristics, the intervals from cardiac arrest to defined events and ambulance service interventions 
are shown in Table 1. There were no significant differences between the two treatment groups in terms of 
baseline characteristics and cardiac arrest background variables. All patients presented with witnessed VF out-
of-hospital cardiac arrest. Three patients in each group had ventricular fibrillation that was refractory to shock 
and drug treatment and were transported to hospital without ROSC. 
 
Angiographic characteristics 
The coronary angiographic findings are summarised in Table 2. Time to coronary angiography was shorter in the 
intervention arm compared with the control arm (100[75 to 113] versus132[93 to 187]; median difference 32, 95% 
CI -9 to 101; P=0.08). The incidence of culprit artery occlusion (responsible for the OHCA) was 44% in the 
intervention group versus 50% in the control group (OR 0.6, 95% CI 0.1 to 2.3; P=0.7).  
 
Primary and Secondary Clinical Outcomes 
The primary clinical endpoint of 30-day all-cause mortality (Table 3) was similar between both study arms 
(Intervention 9/18, 50% vs. Control 6/15, 44%; OR 0.6, 95% CI 0.2 to 2.9; P=0.73). Good neurological function 
evaluated at discharge, capped at 30 days, was similar in both groups (Intervention 9/18, 50% vs. Control 7/15, 
47%; OR 1.1, 95% CI 0.3 to 4; P>0.99) (online supplement). The secondary (clinical) composite endpoint of in-
hospital MACCE occurred in 11/18 in the Intervention arm compared with 6/15 in the control arm (61% vs. 53% 
respectively; OR 1.4, 95% CI 0.4 to 4.9; P=0.73). One stroke occurred in the control arm, one patient in the 
intervention arm and two in the control arm underwent further revascularisation and minor bleeding occurred in 
one patient in the intervention arm. The secondary endpoint of 6-month all-cause mortality was 9/17 (53%) in the 
intervention arm and 6/10 (60%) in the control arm (OR 0.75, 95% CI 0.2 to 3.8; P>0.99). One third of patients in 
both groups developed sepsis. Vascular complications occurred in one patient in the control arm. Four patients in 
the intervention group and two patients in the control group required mechanical circulatory support in the form of 
intra-aortic balloon pump insertion. Length of stay was the same in the two groups (intervention: 4.5, versus 
control:4.5, median difference 0, 95% CI -2 to 8; P=0.19). 
 
The Kaplan-Meier 30-day survival curve is shown in Figure 2 (intervention versus control: HR 1.7, 95% CI 0.3 to 
10.5; P=0.6). In both study arms, a marked attrition in survival was seen between Day 0 and Day 4, with 25% of 
patients dead in the Intervention arm and 17% in the Control arm (overall 21%). No further patients died between 
Day 4 and Day 30. Administration of amiodarone was associated with increased 30-day mortality (HR 11.5, 95% 
CI 1.04 to 126; P=0.04). Pre-hospital ROSC (HR 0.1, 95% CI 0.01 to 0.7; P=0.02), and cardiac arrest in a public 
location (HR 0.05, 95% CI 0.004 to 0.45; P=0.01) were associated with a lower mortality. The performance of 
coronary angiography was found to negatively influence 30-day mortality (HR 0.15, 95% CI 0.03 to 0.71; 
P=0.02); however, after adjustment for pre-hospital factors, there was no influence on 30-day mortality (HR 0.41, 
95% CI 0.05 to 3.5; P=0.4), Figure 3. 
Discussion 
We demonstrated that it is possible to complete a randomised controlled trial comparing a pre-hospital triage 
system involving delivery of the OHCA patient to a CAC with access to 24/7 interventional cardiology facilities 
and receipt of a post-cardiac arrest care bundle with the current standard of care in a population of OHCA 
patients without STE. The main finding of this pilot trial is that performing a large-scale randomised controlled 
trial is safe, feasible and acceptable. The feasibility of randomisation was demonstrated as follows: (1) 
recruitment of all adult witnessed shockable OHCA of presumed cardiac cause exceeded the expected rate. (2) 
It was possible to set up a fast track, rapid intervention service in a single CAC 24/7. (3) Protocol adherence was 
excellent in the intervention arm. (4) Data completeness was acceptable with documentation of the primary 
outcome in 83% and secondary outcomes in 80%. 
 
Based on the findings of the trial pilot, the decision to exclude the refractory cohort from the main trial was made 
based on 1) logistical challenges of on-scene extrication, transport and performing coronary angiography during 
mechanical CPR (m-CPR). 2) Poor outcomes relative to the cohort of patients achieving ROSC. 3) The 
identification that this was a predictor of 30-day mortality. Furthermore, not all frontline vehicles carry m-CPR 
devices, which may prevent shock-refractory patients receiving the same treatment in the main trial. The 
PARAMEDIC trial (LUCAS m-CPR device) showed a 5% lower survival rate (significant) in patients with 
shockable rhythms who received mechanical CPR, although this was not the primary objective of the trial, and 
should be interpreted with caution.30Furthermore, removal of this cohort will reduce the likelihood of post 
randomisation identification of STE (10%). 
 
Outcome was ascertained in 83%; to improve this we will make use of the NHS information centre; in the 
PARAMEDIC trial, this enabled 99% follow-up at 30-days.30Where data cannot be collected in hospital we plan to 
make use of the London Ambulance Clinical Audit and Research Unit (CARU) and National Institute for 
Cardiovascular Outcomes Research (NICOR). Because of the geographical position of St Thomas Hospital, a 
large proportion of the standard of care arm were delivered to a CAC; we anticipate that expanding the trial 
across London will reduce the proportion of patients in the control arm taken straight to the cardiac 
catheterisation laboratory. 
 
The International Liaison Committee on Resuscitation (ILCOR) suggests transport of all post-arrest patients to a 
cardiac arrest centre with 24/7 access to interventional cardiology facilities.19-22 There has been variable uptake 
of such a strategy in this cohort; this may be duein part to the lack of randomised data, the need for coordination 
of organised systems of care, and the heterogeneity of the non-STE population; thus emphasising the need for a 
randomised controlled trial.  
 
Our study is consistent with well-established predictors of survival, including ROSC pre-hospital and cardiac 
arrest in a public location. The predictor of mortality identified was administration of amiodarone, this is likely to 
represent refractory arrhythmia rather than the effect of amiodarone itself. These are supported by findings in the 
recently published “amiodarone versus lignocaine and placebo trial in OHCA”, where no difference in survival 
was shown, with a higher mortality in those with unwitnessed arrest.31 Coronary angiography was performed in 
all patients in the intervention group and just under 80% of control, suggesting that coronary angiography was 
clinically indicated in the latter. The time to coronary angiography was shorter in the intervention arm because of 
immediate delivery to a CAC, but this did not reach statistical significance in these few patients. In those who 
underwent coronary angiography, significant coronary disease was identified in two thirds of patients, with a 
culprit lesion in just over half, which is consistent with published registry data.16,32 Howevershould be interpreted 
with caution because this was a small patient cohort that may not be representative of the patient population.The 
findings from this pilot also suggest that the absence of STE on the post-arrest ECG does not exclude acute 
ischemia.15 The overall mortality, albeit low, is representative of the VF OHCA population that achieves ROSC 
pre-hospital and is consistent with previous figures published by the London Ambulance Service. 33 
 
Limitations 
This study was a pilot randomised trial to demonstrate safety and feasibility; the study was not powered to show 
a difference in 30-day mortality, neurological endpoints or the composite of in-hospital MACCE. The full planned 
trial with a sample size of 860, will aim to address these questions.The catchment area around St Thomas 
Hospital was small and may not be representative of the population. Although this pilot provided an indication of 
the underlying event rate and incidence of occlusive coronary artery disease, the effect size and therefore 
sample size calculations were based on a combination of studies. These included the above pilot findings, Pan-
London Annual OHCA audit data, published registry data (incidence of occlusive disease in OHCA in absence of 
STE) and randomised trials of reperfusion therapy.13,33-35 Based on findings from the trial pilot, inclusion criteria 
were amended to remove the shock-refractory cohort from the main trial because logistical challenges of 
managing these patients, and in order to reduce the likelihood of post-randomisation identification of STE. 
Delayed prognostication (≥72 hours) to prevent the premature withdrawal of life-sustaining treatment was not 
formally instituted in the pilot as this was not the current standard of care; however this will be mandated during 
the full trial.36 
 
Conclusions 
This pilot study demonstrated that a large-scale randomised trial comparing the delivery of a cardiac arrest 
patient without STE to the catheter laboratory at a dedicated cardiac arrest receiving centre with a view to 
immediate reperfusion and delivery of post-resuscitation care, compared with standard care, is safe and feasible. 
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 Total Intervention Control P value 
Angiogram  32/36 (89%) 18/18 (100%) 14/18 (78%) 0.10 
Time to Angiography (minutes)  100; 75 to 113 132; 93 to 187 0.08 
Coronary Artery Disease (>50% stenosis) 20/32 (63%) 12/18 (67%) 8/14 (57%) 0.72 
Number of diseased vessels      
0 10/32 (31%) 6/18 (33%) 4/14 (21%) >0.99 
1 4/32 (13%) 2/18(11%) 2/14 (14%) >0.99 
2 4/32 (13%) 2/18(11%) 2/14 (14%) 0.47 
≥3 12/32 (38%) 8/18 (44%) 4/14 (29%) 0.47 
Unknown 2/32 (6%) 0/32 (0%) 2/14 (6%) 0.18 
Culprit: Revascularisation 15/32 (47%) 8/18 (44%) 7/14 (50%) 0.71 
1. PCI 13/15 (87%) 7/8 (88%) 6/7 (86%) >0.99 
LMS 0/13 (0%) 0/7 (0%) 0/6 (0%) >0.99 
LAD 5/13 (38%) 3/7 (43%) 2/6 (33%) >0.99 
Cx 3/13 (23%) 1/7 (14%) 2/6 (33%) 0.56 
RCA 5/13 (38%) 3/7 (43%) 2/6 (33%) >0.99 
2. CABG 2/15 (13%) 1/8 (13%) 1/7 (14%) >0.99 
Table 1Angiographic characteristics of the intervention and control arm. Categorical variables are presented as 
counts and percentages n/N (%); times are displayed as mean±SD. Abbreviations: PCI percutaneous coronary 
intervention, LMA left main stem, LAD left anterior descending artery, CX circumflex artery, RCA right coronary 
artery, CABG coronary artery bypass grafting. 
 Total Intervention Control P value 
Angiogram  32/36 (89%) 18/18 (100%) 14/18 (78%) 0.10 
Time to Angiography (minutes)  100; 75 to 113 132; 93 to 187 0.08 
Coronary Artery Disease (>50% stenosis) 20/32 (63%) 12/18 (67%) 8/14 (57%) 0.72 
Number of diseased vessels      
0 10/32 (31%) 6/18 (33%) 4/14 (21%) >0.99 
1 4/32 (13%) 2/18(11%) 2/14 (14%) >0.99 
2 4/32 (13%) 2/18(11%) 2/14 (14%) 0.47 
≥3 12/32 (38%) 8/18 (44%) 4/14 (29%) 0.47 
Unknown 2/32 (6%) 0/32 (0%) 2/14 (6%) 0.18 
Culprit: Revascularisation 15/32 (47%) 8/18 (44%) 7/14 (50%) 0.71 
1. PCI 13/15 (87%) 7/8 (88%) 6/7 (86%) >0.99 
LMS 0/13 (0%) 0/7 (0%) 0/6 (0%) >0.99 
LAD 5/13 (38%) 3/7 (43%) 2/6 (33%) >0.99 
Cx 3/13 (23%) 1/7 (14%) 2/6 (33%) 0.56 
RCA 5/13 (38%) 3/7 (43%) 2/6 (33%) >0.99 
2. CABG 2/15 (13%) 1/8 (13%) 1/7 (14%) >0.99 
Table 2Angiographic characteristics of the intervention and control arm. Categorical variables are presented as 
counts and percentages n/N (%); times are displayed as mean±SD. Abbreviations: PCI percutaneous coronary 
intervention, LMA left main stem, LAD left anterior descending artery, CX circumflex artery, RCA right coronary 
artery, CABG coronary artery bypass grafting. 
 
 
 Total Intervention Control OR (95% CI)* Pvalue 
Primary Endpoint      
30-day all cause mortality 15/33 (45%) 9/18 (50%) 6/15 (40%) 0.6 (0.2 to 2.9) 0.73 
Secondary Endpoints      
CPC 1/2 at 30 days 16/32 (50%) 9/18 (50%) 7/14 (50%) 1.0 (0.3 to 3.6) >0.99 
MACCE* 19/33 (58%) 11/18 (61%) 8/15 (53%) 1.4 (0.4 to 4.9) 0.73 
Death 15/33 (45%) 9/18 (50%) 6/15 (40%) 0.6 (0.2 to 2.9) 0.73 
MI 0/33 (0%) 0/18 (0%) 0/15 (0%) N/A >0.99 
Further revascularization 3/33 (9%) 1/18(6%) 2/15 (13%) 0.4 (0 to 3.7) 0.58 
Stroke 1/33 (3%) 1/18 (6%) 0/15 (0%) N/A >0.99 
Bleeding 1/33(3%) 1/18 (6%) 0/15 (0%) N/A >0.99 
Vascular complications 1/33 (3%) 0/18 (0%) 1/15 (7%) 0 (0 to 7.5) 0.5 
6-month all cause mortality 15/27 (56%) 9/17 (53%) 6/10 (60%) 0.75 (0.2 to 3.8) >0.99 
Length of Stay* 4.5 (0 to 11) 4.5 (0 to 7.3) 4.5 (0 to 19) 0 (-2 to 8) 0.19 
CPR Related Complications 1/33 (3%) 1/18 (6%) 0/15 (0%) N/A >0.99 
Renal Replacement Therapy 2/33 (3%) 1/18 (6%) 1/15 (7%) 0.8 (0 to 17) >0.99 
Sepsis 11/33 (33%) 6/18 (33%) 5/15 (33%) 1.0 (0.2 to 4.5) >0.99 
Mechanical Circulatory Support 6/33 (18%) 4/18 (22%) 2/15 (13%) 1.6 (0.3 to 9.5) 0.68 
Table 3 Primary and secondary outcomes, length of stay and other in-hospital complications described overall 
and for both arms of the trial. Categorical variables are presented as counts and percentages n/N (%); *days are 
displayed as median and interquartile range (IQR). Abbreviations: CPC cerebral performance category score, 
MACCE major adverse cardiovascular and cerebrovascular events, CPR cardiopulmonary resuscitation. 
 
